GLP-1 Weight Loss Drug Denied? How to Appeal

Ozempic, Wegovy, Mounjaro, and Zepbound — GLP-1 receptor agonist medications — have transformed the clinical treatment of obesity and type 2 diabetes. For millions of Americans, they represent a medically meaningful breakthrough backed by substantial clinical evidence. Yet getting insurance to pay for them remains a battle. GLP-1 drugs cost $900 to $1,300 or more per month at retail prices, and insurers have developed an overlapping toolkit of strategies to limit or block access. If your GLP-1 claim was denied, you have real options to fight back.

Why Insurers Deny GLP-1 Medications

Insurance companies use several distinct strategies to deny GLP-1 coverage, often applying multiple barriers simultaneously.

Formulary exclusion for weight loss indication. Many employer health plans and individual market plans explicitly exclude weight loss medications from their formulary, regardless of FDA approval. This exclusion does not apply to GLP-1 drugs prescribed for type 2 diabetes (where semaglutide/Ozempic and tirzepatide/Mounjaro have been FDA-approved for years), but Wegovy and Zepbound — approved specifically for chronic weight management — are often excluded. If your physician prescribed a GLP-1 for obesity (ICD-10: E66.01 — morbid obesity due to excess calories; E66.09 — other obesity), the formulary exclusion may apply. If the prescription is for type 2 diabetes (ICD-10: E11.65 — type 2 diabetes with hyperglycemia) or cardiovascular risk reduction, the coverage picture changes significantly.

Step therapy (fail-first) requirements. Plans that do cover GLP-1s often require you to try and fail less expensive alternatives first — typically metformin, SGLT-2 inhibitors, or older weight management medications. Step therapy must be documented with specific prior treatment records and failure notes in the clinical chart. The American Diabetes Association (ADA) 2024 Standards of Care support early use of GLP-1 receptor agonists in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, providing a strong clinical basis to bypass step therapy.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization denials based on BMI or comorbidity criteria. Plans that cover GLP-1s for obesity typically impose prior authorization criteria based on BMI thresholds (commonly ≥30, or ≥27 with a weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or sleep apnea) and documentation of a comprehensive weight management program. If your documentation does not clearly establish these criteria, prior authorization may be denied.

Cardiovascular indication coverage gaps. As of 2024–2026, semaglutide (Wegovy) carries an FDA-approved indication for reducing cardiovascular risk in adults with obesity or overweight and established cardiovascular disease. Medicare Part D coverage was expanded for this indication. Despite this, some commercial plans and Medicare Part D plans still deny coverage by citing formulary exclusions rather than the cardiovascular indication.

Off-label use denial. Some prescribers use drugs approved for one condition (e.g., Ozempic for diabetes) to treat another (e.g., obesity). Insurers may deny these uses as off-label. However, off-label prescribing is standard medical practice and is not automatically excludable — particularly when supported by clinical guidelines such as the ADA Standards of Care or Obesity Medicine Association (OMA) guidelines.

How to Appeal a GLP-1 Drug Denial

Step 1: Identify the Exact Denial Reason and the ICD-10 Code on the Claim

Request the denial reason in writing and confirm the ICD-10 diagnosis code under which the drug was prescribed. This matters enormously: a GLP-1 prescribed for E11.x (type 2 diabetes) is evaluated under a different coverage category than one prescribed for E66.x (obesity). If the code is incorrect, a simple correction may resolve the denial without a formal appeal.

Step 2: Obtain a Letter of Medical Necessity From Your Prescribing Physician

Your physician should write a detailed letter documenting your BMI, qualifying comorbidities (type 2 diabetes, hypertension, dyslipidemia, sleep apnea, ASCVD), prior weight management attempts, and the clinical rationale for GLP-1 therapy. The letter should cite the 2024 ADA Standards of Care, the Obesity Medicine Association Clinical Practice Guidelines, or the American Heart Association/American College of Cardiology (AHA/ACC) cardiovascular prevention guidelines, as applicable.

Step 3: Challenge Step Therapy Requirements With Documented Treatment History

If the denial cites incomplete step therapy, provide documentation of all prior treatments attempted — including medications, dosages, duration, and reasons for failure or discontinuation. If your physician determines that step therapy is clinically inappropriate for your specific case (for example, due to intolerance of prior agents, contraindications, or established cardiovascular disease requiring GLP-1 specifically), the letter of medical necessity should explicitly address why step therapy exception criteria are met.

Step 4: Invoke the Cardiovascular Indication if Applicable

If you have established atherosclerotic cardiovascular disease (ASCVD) and your physician prescribed semaglutide for cardiovascular risk reduction, your appeal should specifically cite the SELECT trial results (published 2023 in NEJM) and the FDA approval of Wegovy for this indication. This argument is particularly powerful for Medicare Part D appeals, where CMS guidance has expanded coverage for this use.

Step 5: File the Internal Appeal and Request Peer-to-Peer Review

Submit your formal internal appeal within the deadline specified in your denial (typically 30–180 days). Include the physician letter, supporting clinical guidelines, step therapy documentation, and a clear argument addressing each stated denial reason. Request a peer-to-peer review allowing your prescribing physician to speak directly with the insurer's pharmacist reviewer.

Step 6: Escalate to External Independent Review: Complete Guide" class="auto-link">External Review or State Insurance Commissioner

If internal appeal fails, file for external review — an independent clinical review where a third-party physician evaluates whether the denial was medically appropriate. GLP-1 drug denials have a meaningful external review overturn rate, particularly when the cardiovascular indication applies. You can also file a complaint with your state insurance commissioner, particularly if the plan applies a formulary exclusion inconsistent with state mandates for obesity treatment coverage.

What to Include in Your Appeal

• Denial letter with the specific formulary exclusion or prior authorization criteria cited
• ICD-10 diagnosis code on the claim and correction if the code was wrong
• Physician letter of medical necessity with BMI, qualifying comorbidities, and treatment history
• Documentation of prior step therapy attempts and reasons for failure
• Clinical guideline citations: ADA 2024 Standards of Care, OMA guidelines, AHA/ACC cardiovascular prevention guidelines
• SELECT trial reference and FDA cardiovascular indication approval if ASCVD applies

Fight Back With ClaimBack

GLP-1 denials are among the most winnable insurance appeals when properly documented — particularly for patients with type 2 diabetes, cardiovascular disease, or qualifying comorbidities where clinical guidelines clearly support the prescription. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal